Cantor Fitzgerald: 'ORIC Sell-Off on JNJ RIPTAC Data Way Overdone'
Tweet Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and {REMOVEPT} price target on ORIC Pharmaceuticals (NASDAQ: ORIC).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




